Details

Autor(en) / Beteiligte

• Choi, Hongjo
• Mok, Jeongha
• Kang, Young Ae
• Jeong, Dawoon
• Kang, Hee-Yeon
• Kim, Hee Jin
• Kim, Hee-Sun
• Jeon, Doosoo

Titel

Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011-2017: A Retrospective Cohort Study (Korean TB-POST)

Ist Teil von

• Journal of Korean Medical Science, 2023, 38(5), , pp.1-11

Ort / Verlag

Korea (South): The Korean Academy of Medical Sciences

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• The treatment outcomes of patients with multidrug/rifampin-resistant (MDR/RR) tuberculosis (TB) are important indicators that reflect the current status of TB management and identify the key challenges encountered by TB control programs in a country. We retrospectively evaluated the treatment outcomes as well as predictors of unfavorable outcomes in patients with MDR/RR-TB notified from 2011 to 2017, using an integrated TB database. A total of 7,226 patients with MDR/RR-TB were included. The treatment success rate had significantly increased from 63.9% in 2011 to 75.1% in 2017 ( < 0.001). Among unfavorable outcomes, the proportion of patients who failed, were lost to follow up, and were not evaluated had gradually decreased ( < 0.001). In contrast, TB-related death rate was not significantly changed ( = 0.513), while the non-TB related death rate had increased from 3.2% in 2011 to 11.1% in 2017 ( < 0.001). Older age, male sex, immigrants, low household income, previous history of TB treatment, and comorbidities were independent predictors of unfavorable outcomes. Of the 5,308 patients who were successfully treated, recurrence occurred in 241 patients (4.5%) at a median 18.4 months (interquartile range, 9.2-32.4) after completion treatment. The treatment outcomes of patients with MDR/RR-TB has gradually improved but increasing deaths during treatment is an emerging challenge for MDR-TB control in Korea. Targeted and comprehensive care is needed for vulnerable patients such as the elderly, patients with comorbidities, and those with low household incomes.